Emergency coronary artery bypass graft surgery in abciximab-treated patients (Q40780278)

23 September 2017

title

Emergency coronary artery bypass graft surgery in abciximab-treated patients (English)

1 reference

coronary artery bypass surgery

23 September 2017

main subject

0 references

cardiac surgery

0 references

author name string

J H Lemmer

1

1 reference

23 September 2017

M T Metzdorff

2

1 reference

23 September 2017

A H Krause

3

1 reference

23 September 2017

M A Martin

4

1 reference

23 September 2017

J E Okies

5

1 reference

23 September 2017

J G Hill

6

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 January 2000

1 reference

The Annals of Thoracic Surgery

23 September 2017

published in

1 reference

23 September 2017

volume

69

1 reference

23 September 2017

issue

1

1 reference

23 September 2017

page(s)

90-95

1 reference

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2899%2901132-7

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2899%2901132-7

Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2899%2901132-7

Abciximab and excessive bleeding in patients undergoing emergency cardiac operations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2899%2901132-7

Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2899%2901132-7

Safe use of platelet GP IIb/IIIa inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2899%2901132-7

Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2899%2901132-7

Aprotinin use in patients with dialysis-dependent renal failure undergoing cardiac operations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2899%2901132-7

Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2899%2901132-7

Reporting the results of blood conservation studies: the need for uniform and comprehensive methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2899%2901132-7

In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2899%2901132-7

Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complicatio

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2899%2901132-7

Activated coagulation time: one tube or two?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2899%2901132-7

The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2899%2901132-7

Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2899%2901132-7

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2899%2901132-7

10.1016/S0003-4975(99)01132-7

7 January 2021

Identifiers

DOI

1 reference

23 September 2017

1 reference